Home > About Us
About Vorpal Technologies
Vorpal is a full-service virtual subsidiary, enabling international MedTech innovators to enter Japan on their own terms with transparency, confidence and optionality. Vorpal delivers expert solutions in opportunity assessment, clinical development, regulatory affairs, reimbursement, quality and safety management, supply chain and commercialization.
Vorpal Technologies K.K.
3-3-16 Nihonbashi Hongokucho, Chuo-ku, Tokyo , Japan
Robert E. Claar
Regulatory and Reimbursement Strategy
Clinical Trial Management
Health Economics and Market Access
Designated Marketing Authorization Holder (D-MAH) services
Import and Sales of Medical Devices, In-Vitro Diagnostics (IVD)
Distributor Selection and Management
Post Marketing Surveillance (PMS) studies
KOL Relationship Management
Subsidiary Establishment and Business Advisory
We maintain an ecosystem based on common goals, mutual respect, trust and teamwork
We ensure execution, follow-through and accountaility
We act on needs and opportunities to deliver inspired solutions
We rise to challenges with enthusiasm and tenacity
We conduct ourselves with integrity and transparency
We work to enhance wellness in our local communities and around the world
Robert E. Claar
Chief Executive Officer,
Rob Claar co-founded Vorpal Technologies in 2013 to help create solutions for Japan’s device lag and become the premier pathway into Japan for innovative MedTech solutions.
-Vorpal is a full-service virtual subsidiary, enabling overseas medtech innovators to enter Japan on their own terms with transparency, confidence and optionality. Vorpal delivers expert solutions in clinical development, regulatory affairs, reimbursement, quality and safety management, logistics and market development.
-Prior to Vorpal, Rob founded Junicon K.K., a healthcare market research and strategy consulting firm. Junicon now has a global reach with offices in the US and Europe and strong affiliations in all major markets.
-Rob has nearly three decades of experience in healthcare innovation management, opportunity assessment, strategy development and implementation. He is passionate about developing innovative solutions for access to Japan’s healthcare market.
Vorpal Technologies is the premier regulatory consulting firm for MedTech companies (medical devices and IVD) from the US, Europe and Asia seeking entry into the Japan market. Our portfolio of services includes commercial opportunity assessments and distributor selection in addition to our traditional services of clinical development, regulatory approvals, market access (reimbursement), supply chain management and marketing authorization management.
Through his time with Eli Lilly, Novo Nordisk and Baxter, Tak has developed expertise in sales, marketing and market access, among other areas. His experience spans specialties such as CNS, Diabetes and Anesthesia in addition to surgical specialties such as Spine, CV and Neuro. Tak joined Vorpal in April, 2019 to lead the charge of introducing innovation into the Japan market.
Karl (Jiangang) Yin established Shanghai MedTech Enterprise Management Consulting Co., Ltd in 2004, which evolves into MedBridge group in 10 years and now boasts six subsidiary companies. Karl has extensive experience in setting strategic direction, integrating company resources, collaborating with stakeholders and leading his company through different challenges to great success. Karl worked for renowned companies such as Siemens and Smith & Nephew in the early years of his career. He holds a bachelor’s degree from Shanghai Jiaotong University and a master’s degree from East China Normal University.
Yoav has been bringing innovative technologies to the Japanese market and one of them is Smartheart, the only mobile hospital-grade electrocardiogram for personal use that can be connected to a smartphone. He is the co-founder and CEO of HekaBio Digital Health, and was the President and Chair of EZ Invest Securities Co., Ltd. Yoav graduated from The Hebrew University of Jerusalem and has been living in Japan for 20 years.